Psychiatry journals have retracted two papers evaluating a schizophrenia drug after a university in Japan flagged issues, such as a lack of written informed consent.
The papers—published in Human Psychopharmacology: Clinical & Experimental in 2012 and Psychiatry and Clinical Neurosciences in 2014—examined the safety and effectiveness of an antipsychotic drug in patients with schizophrenia.